BEACON CRC (binimetinib [BINI], encorafenib [ENCO], and cetuximab [CTX] combined to treat BRAF-mutant metastatic colorectal cancer [mCRC]): A multicenter, randomized, open-label, three-arm phase III study of ENCO plus CTX plus or minus BINI vs irinotecan (IRI)/CTX or infusional 5-fluorouracil/folinic acid/IRI (FOLFIRI)/CTX with a safety lead-in of ENCO + BINI + CTX in patients (Pts) with BRAFV600E mCRC
Modulating a complex system carries the possibility of unintended effects that require careful study
Holder, D
Moreover, although PET-based fluorescence switching enables effective off-on activation, the extent of initial quenching and the magnitude of signal recovery upon activation are highly dependent on the COFs electronic structure and local microenvironment, necessitating precise molecular engineering to balance diagnostic signal-to-noise ratio with therapeutic output
Not just the scale moving again, but I actually had more energy
Macrophages in Tissue Repair, Regeneration, and Fibrosis